Expression Of Androgen Receptor, Estrogen Receptor And Progesterone Receptor In Endometrial Carcinoma (Immunohistochemical Study)
DOI:
https://doi.org/10.21276/apalm.2726Keywords:
Endometrial adenocarcinoma, androgen receptor, estrogen receptor, progesterone receptorAbstract
BACKGROUND
Endometrial carcinoma is the most common pelvic genital malignancy and 4th most frequently diagnosed cancer in females with it’s incidence being 4.3/ 1 lac females.
METHODS:
Thirty histologically proven cases of endometrial carcinoma were taken up for the study in pathology department. Immunohistochemistry for expression of androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) was done using Biocare system kit.
RESULTS:
80% of the cases were in 5th and 6th decade of life. Bleeding per vagina and post menopausal bleeding were the main complaints. Out of the total 22 abdominal hysterectomies the size of tumor varied from 1cm to >4cm. All were adenocarcinoma with 20 being moderately differentiated and only 2 being well differentiated.
AR was positive in 8 cases with ER and PR being positive in 16 and 21 cases respectively with score being also the same. Receptor positivity decreased with increasing grade of the tumor.
CONCLUSION:
ER and PR status are important prognostic biomarkers which also predict response to antihormonal therapy in endometrial carcinoma. AR expression though associated with low grade tumors , but still is a driver for tumor growth and therefore a potential therapeautic target. Anti androgen therapy - enzalutamide may inhibit proliferation of AR positive primary endometrial cancer cells.
References
2. National Cancer Institute surveillance, epidemiology and end results program. Cancer stat facts: Endometrial Cancer [Internet]. USA, New York: SEER;2017[updated 2017 Jun 28; cited on 2017 Nov 21]. Available from . https://seer.cancer.gov/ statfacts/html/corp.html.
3. Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Oyan AM, et al. Androgen receptor as potential therapeautic target in metastatic endometrial cancer. Oncotarget [Internet]. 2016 Aug [cited on 2017 Nov 22];7(31):49289-98. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226508/ DOI:10.18632/oncotarget.10334.
4. Tariq AA. Risk factors for Endometrial cancer. Ces. Gynek. 2013;78(5):448-59.
5. Kamal AM, Bulmer JN, De Cruze SB, Stringfellow HF, Martin–Hirsch P, Hapangama DK. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br. J. Cancer [Internet]. 2015 Dec [cited on 2017 Nov28];114:688-96. Available from: https://www.bjcancer.com DOI:10.1038/bjc.2016.16.
6. Modi M, Nilkanthe R, Trivedi M. Detailed Histopathological Study of Endometrial Carcinoma, and Importance of Immunohistochemistry. Am J Clin Path. 2016 Sept;146(1):74-7.
7. Kato J, Seto T. Correlation of androgen receptors with histological differentiation in human endometrial carcinomas. Acta Obstet Gynecol Scand. 1985;64(3):209-12.
8. Bender D, Buekers T, Leslie KK. Hormones and Receptors in Endometrial Cancer. Proc Obstet Gynaecol. 2011 Jul;2(1):1-25.
9. Waqar S, Khan SA, Sarfraz T, Waqar S. Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor. Pak J Med Sci. 2018 Mar;34(2):266–71.
10. McCarty KS, Jr., Barton TK, Fetter BF, Creasman WT, McCarty KS, Sr. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol. 1979;96(1):171-83.
11. Mahdi Z, Abdulfatah E, Pardeshi V, Hassan O, Schultz D, Morris R, et al. The Impact of Androgen Receptor Expression on Endometrial Carcinoma Recurrence and Survival. Int J Gynecol Pathol. 2017 Sep;36(5):405-11.
12. Guan J, Xie L, Luo X, Yang B, Zhang H, Zhu Q, et al. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. J Gynecol Oncol [Internet]. 2019 Jan [cited on 2019 Aug 20]; 30(1): e13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304404/ DOI: 10.3802/jgo.2019.30.e13
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Suruchi Mangal, Manisha Sharma, Mridu Manjari, Rahul Mannan, Sunit Tandon
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
